Pharmacokinetics of second-line antituberculosis drugs after multiple administrations in healthy volunteers

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 8, 2015, Pages 4429-4435

  Park, Sang In ^a   Oh, Jaeseong ^a   Jang, Kyungho ^a   Yoon, Jangsoo ^a   Moon, Seol Ju ^a   Park, Jong Sun ^b   Lee, Jae Ho ^b   Song, Junghan ^b   Jang, In Jin ^a   Yu, Kyung Sang ^a   Chung, Jae Yong ^b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; CYCLOSERINE; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLONE DERIVATIVE; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; AREA UNDER THE CURVE; CLINICAL TRIAL; DRUG MONITORING; HUMAN; MALE; NORMAL HUMAN; PROCEDURES; YOUNG ADULT;

ADULT; AMINOSALICYLIC ACID; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; CYCLOSERINE; DRUG MONITORING; FLUOROQUINOLONES; HEALTHY VOLUNTEERS; HUMANS; KANAMYCIN; LEVOFLOXACIN; MALE; PROTHIONAMIDE; PYRAZINAMIDE; STREPTOMYCIN; YOUNG ADULT;

EID: 84939795357     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00354-15     Document Type: Article

References (15)

1. Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, Van Soolingen D, Jensen P, Bayona J. 2010. Multidrug-resistant and extensively drugresistant tuberculosis: a threat to global control of tuberculosis. Lancet 375:1830-1843. http://dx.doi.org/10.1016/S0140-6736(10)60410-2.
2. Falzon D, Jaramillo E, Schunemann HJ, Arentz M, Bauer M, Bayona J, Blanc L, Caminero JA, Daley CL, Duncombe C, Fitzpatrick C, Gebhard A, Getahun H, Henkens M, Holtz TH, Keravec J, Keshavjee S, Khan AJ, Kulier R, Leimane V, Lienhardt C, Lu C, Mariandyshev A, Migliori GB, Mirzayev F, Mitnick CD, Nunn P, Nwagboniwe G, Oxlade O, Palmero D, Pavlinac P, Quelapio MI, Raviglione MC, Rich ML, Royce S, Rusch-Gerdes S, Salakaia A, Sarin R, Sculier D, Varaine F, Vitoria M, Walson JL, Wares F, Weyer K, White RA, Zignol M. 2011. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 38:516-528. http://dx.doi.org/10.1183/09031936.00073611.
3. Dartois V, Barry CE. 2010. Clinical pharmacology and lesion penetrating properties of second- and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosis. Curr Clin Pharmacol 5:96-114. http://dx.doi.org/10.2174/157488410791110797.
4. Alsultan A, Peloquin CA. 2014. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs 74:839-854. http://dx.doi.org/10.1007/s40265-014-0222-8.
5. Garcia-Prats AJ, Donald PR, Hesseling AC, Schaaf HS. 2013. Secondline antituberculosis drugs in children: a commissioned review for the World Health Organization 19th Expert Committee on the Selection and Use of Essential Medicines. World Health Organization, Geneva, Switzerland.
6. Han M, Jun SH, Lee JH, Park KU, Song J, Song SH. 2013. Method for simultaneous analysis of nine second-line anti-tuberculosis drugs using UPLC-MS/MS. J Antimicrob Chemother 68:2066-2073. http://dx.doi.org/10.1093/jac/dkt154.
7. Douglas JG, McLeod MJ. 1999. Pharmacokinetic factors in the modern drug treatment of tuberculosis. Clin Pharmacokinet 37:127-146. http://dx.doi.org/10.2165/00003088-199937020-00003.
8. Peloquin CA. 2002. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 62:2169-2183. http://dx.doi.org/10.2165/00003495-200262150-00001.
9. Anonymous. 2008. Cycloserine. Tuberculosis 88:100-101. http://dx.doi.org/10.1016/S1472-9792(08)70007-6.
10. Liwa AC, Schaaf HS, Rosenkranz B, Seifart HI, Diacon AH, Donald PR. 2013. para-Aminosalicylic acid plasma concentrations in children in comparison with adults after receiving a granular slow-release preparation. J Trop Pediatr 59:90-94. http://dx.doi.org/10.1093/tropej/fms053.
11. Lee HW, Kim DW, Park JH, Kim SD, Lim MS, Phapale PB, Kim EH, Park SK, Yoon YR. 2009. Pharmacokinetics of prothionamide in patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 13:1161-1166.
12. Chien SC, Rogge MC, Gisclon LG, Curtin C, Wong F, Natarajan J, Williams RR, Fowler CL, Cheung WK, Chow AT. 1997. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob Agents Chemother 41:2256-2260.
13. Tachibana M, Tanaka M, Masubuchi Y, Horie T. 2005. Acyl glucuronidation of fluoroquinolone antibiotics by the UDP-glucuronosyltransferase1A subfamily in human liver microsomes. Drug Metab Dispos 33:803-811. http://dx.doi.org/10.1124/dmd.104.003178.
14. Senggunprai L, Yoshinari K, Yamazoe Y. 2009. Selective role of sulfotransferase 2A1 (SULT2A1) in the N-sulfoconjugation of quinolone drugs in humans. Drug Metab Dispos 37:1711-1717. http://dx.doi.org/10.1124/dmd.109.027441.
15. Anonymous. 2008. Moxifloxacin. Tuberculosis 88:127-131. http://dx.doi.org/10.1016/S1472-9792(08)70016-7.